AbbVie's study also met all secondary goals, with 64.1% patients on Qulipta seeing a 50% or more reduction in the average ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

US pharma major AbbVie (NYSE: ABBV) today announced positive top-line results from its Phase III TEMPLE multicenter, ...

This was the stock's third consecutive day of losses.

In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.

Shares of AbbVie (ABBV) were in the spotlight on Wednesday after the company announced positive results from a late-stage ...

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a ...

AbbVie (NYSE:ABBV) said on Wednesday that its late-stage study testing atogepant in comparison with the highest dose of ...

Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a ...

Bavarian Nordic has sold a PRV for $160m, a day after the FDA announced a new scheme utilising the fast-track tickets.